Form 8-K - Current report:
SEC Accession No. 0000059478-24-000242
Filing Date
2024-10-30
Accepted
2024-10-30 07:05:55
Documents
16
Period of Report
2024-10-30
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lly-20241030.htm   iXBRL 8-K 50426
2 EX-99.1 q324lillysalesandearningsp.htm EX-99.1 237341
7 logoa31a.jpg GRAPHIC 14287
  Complete submission text file 0000059478-24-000242.txt   552741

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lly-20241030.xsd EX-101.SCH 4497
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT lly-20241030_def.xml EX-101.DEF 19611
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lly-20241030_lab.xml EX-101.LAB 37995
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lly-20241030_pre.xml EX-101.PRE 20830
18 EXTRACTED XBRL INSTANCE DOCUMENT lly-20241030_htm.xml XML 10543
Mailing Address LILLY CORPORATE CENTER DROP CODE 1094 INDIANAPOLIS IN 46285
Business Address LILLY CORPORATE CTR DROP CODE 1094 INDIANAPOLIS IN 46285 3172762000
ELI LILLY & Co (Filer) CIK: 0000059478 (see all company filings)

EIN.: 350470950 | State of Incorp.: IN | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-06351 | Film No.: 241407422
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)